{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:52:34Z","timestamp":1784735554650,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Pharmaceutical Society","award":["SHYXHZP-2021-002"],"award-info":[{"award-number":["SHYXHZP-2021-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-023-00606-0","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:02:38Z","timestamp":1700305358000},"page":"561-572","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sacubitril\/Valsartan in Heart Failure with Hypertension Patients: Real-World Experiences on Different Ages, Drug Doses, and Renal Functions"],"prefix":"10.1007","volume":"30","author":[{"given":"Yingyun","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianzhou","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1151-9057","authenticated-orcid":false,"given":"Xiaolan","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"issue":"3","key":"606_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/01.hjh.0000199801.72563.6f","volume":"24","author":"CM Lawes","year":"2006","unstructured":"Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of Disease 2000. Part 1: estimates of blood pressure levels. J Hypertens. 2006;24(3):413\u201322. https:\/\/doi.org\/10.1097\/01.hjh.0000199801.72563.6f.","journal-title":"J Hypertens"},{"issue":"1","key":"606_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/jch.13437","volume":"21","author":"Y Huo","year":"2019","unstructured":"Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W. Efficacy and safety of sacubitril\/valsartan compared with olmesartan in Asian patients with Essential Hypertension: a randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2019;21(1):67\u201376. https:\/\/doi.org\/10.1111\/jch.13437.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"606_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/hr.2014.169","volume":"38","author":"JB Park","year":"2015","unstructured":"Park JB, Kario K, Wang JG. Systolic Hypertension: an increasing clinical challenge in Asia. Hypertens Res. 2015;38(4):227\u201336. https:\/\/doi.org\/10.1038\/hr.2014.169.","journal-title":"Hypertens Res"},{"key":"606_CR4","volume-title":"Pharmacological treatment of Hypertension in adults","author":"Guideline for the","year":"2021","unstructured":"Guideline for the. Pharmacological treatment of Hypertension in adults. Geneva: World Health Organization; 2021."},{"issue":"4","key":"606_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3760\/cma.j.issn.1671-7368.2019.04.002","volume":"18","author":"Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice","year":"2019","unstructured":"Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of General Practice. Guideline for primary care of Hypertension (2019). Chin J Gen Pract. 2019;18(4):301\u201313. https:\/\/doi.org\/10.3760\/cma.j.issn.1671-7368.2019.04.002.","journal-title":"Chin J Gen Pract"},{"issue":"5","key":"606_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3969\/j.issn.1000-3614.2015.05.002","volume":"30","author":"J Zhang","year":"2015","unstructured":"Zhang J, Zhang Y. China heart failure registry study\u2014a multicenter, prospective investigation for preliminary analysis on etiology, clinical features and treatment in heart failure patients. Chin Circulation J. 2015;30(5):413\u20136. https:\/\/doi.org\/10.3969\/j.issn.1000-3614.2015.05.002.","journal-title":"Chin Circulation J"},{"issue":"4","key":"606_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/ehjcvp\/pvv031","volume":"1","author":"V Katsi","year":"2015","unstructured":"Katsi V, Skalis G, Pavlidis AN, Makris T, Nihoyannopoulos P, Tousoulis D, Kallikazaros I. Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial Hypertension? Eur Heart J Cardiovasc Pharmacother. 2015;1(4):260\u20134. https:\/\/doi.org\/10.1093\/ehjcvp\/pvv031.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"606_CR8","doi-asserted-by":"publisher","first-page":"e00794","DOI":"10.1002\/prp2.794","volume":"9","author":"AL Eadie","year":"2021","unstructured":"Eadie AL, Brunt KR, Herder M. Exploring the food and drug administration\u2019s review and approval of entresto (sacubitril\/valsartan). Pharmacol Res Perspect. 2021;9(3):e00794. https:\/\/doi.org\/10.1002\/prp2.794.","journal-title":"Pharmacol Res Perspect"},{"key":"606_CR9","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","volume":"331","author":"C Proudfoot","year":"2021","unstructured":"Proudfoot C, Studer R, Rajput T, Jindal R, Agrawal R, Corda S, Senni M. Real-world effectiveness and safety of sacubitril\/valsartan in Heart Failure: a systematic review. Int J Cardiol. 2021;331:164\u201371. https:\/\/doi.org\/10.1016\/j.ijcard.2021.01.061.","journal-title":"Int J Cardiol"},{"issue":"9722","key":"606_CR10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope LM, Dukat A, B\u00f6hm M, Lacourci\u00e8re Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(09)61966-8.","journal-title":"Lancet"},{"issue":"4","key":"606_CR11","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","volume":"63","author":"K Kario","year":"2014","unstructured":"Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, Zhang Y, Gotou H, Lefkowitz M, Zhang J. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with Hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698\u2013705. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.02002.","journal-title":"Hypertension"},{"issue":"6","key":"606_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","volume":"38","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International society of hypertension global hypertension practice guidelines. J Hypertens. 2020;38(6):982\u20131004. https:\/\/doi.org\/10.1097\/HJH.0000000000002453.","journal-title":"J Hypertens"},{"key":"606_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480","author":"G Mancia Chairperson","year":"2023","unstructured":"Mancia Chairperson G, Kreutz Co-Chair R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank K, Cunha PG, Danser AHJ, de Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fern\u00e1ndez-Alfonso MS, Halimi JM, J\u00e1rai Z, Jelakovi\u0107 B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE, Authors\/Task Force Members. 2023 ESH guidelines for the management of arterial Hypertension the task force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023. https:\/\/doi.org\/10.1097\/HJH.0000000000003480.","journal-title":"J Hypertens"},{"issue":"23","key":"606_CR14","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.jacc.2019.09.063","volume":"74","author":"AM Shah","year":"2019","unstructured":"Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O\u2019Meara E, Ryan JJ, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray JJV, Solomon SD, PARAGON-HF Investigators. Echocardiographic features of patients with Heart Failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2019;74(23):2858\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.063.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"606_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020699","volume":"12","author":"A Di Lenarda","year":"2023","unstructured":"Di Lenarda A, Di Gesaro G, Sarullo FM, Miani D, Driussi M, Correale M, Bilato C, Passantino A, Carluccio E, Villani A, Degli Esposti L, d\u2019Agostino C, Peruzzi E, Poli S, Iacoviello M. Sacubitril\/Valsartan in Heart Failure with reduced ejection fraction: real-world experience from Italy (the REAL.IT Study). J Clin Med. 2023;12(2): 699. https:\/\/doi.org\/10.3390\/jcm12020699.","journal-title":"J Clin Med"},{"issue":"6","key":"606_CR16","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1002\/ehf2.12974","volume":"7","author":"H Zhang","year":"2020","unstructured":"Zhang H, Huang T, Shen W, Xu X, Yang P, Zhu D, Fang H, Wan H, Wu T, Wu Y, Wu Q. Efficacy and safety of sacubitril-valsartan in Heart Failure: a meta-analysis of randomized controlled trials. ESC Heart Fail. 2020;7(6):3841\u201350. https:\/\/doi.org\/10.1002\/ehf2.12974.","journal-title":"ESC Heart Fail"},{"issue":"13","key":"606_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132824","volume":"10","author":"SK Chua","year":"2021","unstructured":"Chua SK, Lai WT, Chen LC, Hung HF. The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and Meta-analysis of randomized controlled trials. J Clin Med. 2021;10(13): 2824. https:\/\/doi.org\/10.3390\/jcm10132824.","journal-title":"J Clin Med"},{"issue":"1","key":"606_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11886-018-0944-4","volume":"20","author":"K Kario","year":"2018","unstructured":"Kario K. The Sacubitril\/Valsartan, a first-in-Class, angiotensin receptor neprilysin inhibitor (ARNI): potential uses in Hypertension, Heart Failure, and Beyond. Curr Cardiol Rep. 2018;20(1):5. https:\/\/doi.org\/10.1007\/s11886-018-0944-4.","journal-title":"Curr Cardiol Rep"},{"issue":"1","key":"606_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40119-021-00252-4","volume":"11","author":"E Houchen","year":"2022","unstructured":"Houchen E, Loefroth E, Schlienger R, Proudfoot C, Corda S, Saha S, Satwase SK, Studer R. Hospitalization rates in patients with Heart Failure and reduced ejection fraction initiating sacubitril\/valsartan or angiotensin-converting enzyme Inhibitors\/angiotensin receptor blockers: a retrospective cohort study. Cardiol Ther. 2022;11(1):113\u201327. https:\/\/doi.org\/10.1007\/s40119-021-00252-4.","journal-title":"Cardiol Ther"},{"issue":"4","key":"606_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004745","volume":"11","author":"O Vardeny","year":"2018","unstructured":"Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril\/valsartan or enalapril: the PARADIGM-HF trial (prospective comparison of angiotensin receptor Neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure). Circ Heart Fail. 2018;11(4): e004745. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.117.004745.","journal-title":"Circ Heart Fail"},{"issue":"10","key":"606_CR21","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1002\/ejhf.580","volume":"18","author":"O Vardeny","year":"2016","unstructured":"Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD. Prospective comparison of ARNI with ACEI to Determine impact on global mortality and morbidity in heart failure (PARADIGM-HF) investigators. Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in Heart Failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016;18(10):1228\u201334. https:\/\/doi.org\/10.1002\/ejhf.580.","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"606_CR22","first-page":"2885","volume":"24","author":"General Practitioner Branch of Chinese Medical Doctor Association","year":"2021","unstructured":"General Practitioner Branch of Chinese Medical Doctor Association. Chinese expert consensus on clinical use of sacubitril\/valsartan for cardiovascular diseases in primary care. Chin Gen Pract. 2021;24(23):2885\u201390.","journal-title":"Chin Gen Pract"},{"issue":"5","key":"606_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4330\/wjc.v4.i5.135","volume":"4","author":"N Lionakis","year":"2012","unstructured":"Lionakis N, Mendrinos D, Sanidas E, Favatas G, Georgopoulou M. Hypertension in the elderly. World J Cardiol. 2012;4(5):135\u201347. https:\/\/doi.org\/10.4330\/wjc.v4.i5.135.","journal-title":"World J Cardiol"},{"issue":"5","key":"606_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10050895","volume":"10","author":"TL To","year":"2022","unstructured":"To TL, Doan TN, Ho WC, Liao WC. Prevalence of frailty among community-dwelling older adults in asian countries: a systematic review and meta-analysis. Healthc (Basel). 2022;10(5): 895. https:\/\/doi.org\/10.3390\/healthcare10050895.","journal-title":"Healthc (Basel)"},{"key":"606_CR25","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijcard.2022.09.050","volume":"371","author":"X Li","year":"2023","unstructured":"Li X, Zuo C, Chen C, Tian D, Li J, Fan L, Li X, Lv Q. Effectiveness and safety evaluation of sacubitril\/valsartan in blood pressure control and clinical outcomes for elderly patients with heart failure and hypertension: a prospective cohort study. Int J Cardiol. 2023;371:244\u201351. https:\/\/doi.org\/10.1016\/j.ijcard.2022.09.050.","journal-title":"Int J Cardiol"},{"issue":"6","key":"606_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40266-022-00951-0","volume":"39","author":"G Bahat","year":"2022","unstructured":"Bahat G, \u0130lhan B, Tufan A, K\u0131l\u0131\u00e7 C, Karan MA, Petrovic M. Hypotension under antihypertensive treatment and Incident hospitalizations of nursing home residents. Drugs Aging. 2022;39(6):477\u201384. https:\/\/doi.org\/10.1007\/s40266-022-00951-0.","journal-title":"Drugs Aging"},{"issue":"7","key":"606_CR27","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455\u201369. https:\/\/doi.org\/10.1093\/eurheartj\/eht386.","journal-title":"Eur Heart J"},{"issue":"8","key":"606_CR28","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s11739-019-02111-6","volume":"14","author":"F Spannella","year":"2019","unstructured":"Spannella F, Marini M, Giulietti F, Rosettani G, Francioni M, Perna GP, Sarzani R. Renal effects of sacubitril\/valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study. Intern Emerg Med. 2019;14(8):1287\u201397. https:\/\/doi.org\/10.1007\/s11739-019-02111-6.","journal-title":"Intern Emerg Med"},{"issue":"11","key":"606_CR29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. PARADIGM-HF investigators and committees. Angiotensin-neprilysin inhibition versus enalapril in Heart Failure. N Engl J Med. 2014;371(11):993\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa1409077.","journal-title":"N Engl J Med"},{"issue":"5","key":"606_CR30","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1161\/CIRCHEARTFAILURE.111.961573","volume":"4","author":"BS Wessler","year":"2011","unstructured":"Wessler BS, Kramer DG, Kelly JL, Trikalinos TA, Kent DM, Konstam MA, Udelson JE. Drug and device effects on peak oxygen consumption, 6-minute walk distance, and natriuretic peptides as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. Circ Heart Fail. 2011;4(5):578\u201388. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.111.961573.","journal-title":"Circ Heart Fail"},{"issue":"2","key":"606_CR31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jchf.2013.11.007","volume":"2","author":"G Savarese","year":"2014","unstructured":"Savarese G, Musella F, D\u2019Amore C, Vassallo E, Losco T, Gambardella F, Cecere M, Petraglia L, Pagano G, Fimiani L, Rengo G, Leosco D, Trimarco B, Perrone-Filardi P. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. JACC Heart Fail. 2014;2(2):148\u201358. https:\/\/doi.org\/10.1016\/j.jchf.2013.11.007.","journal-title":"JACC Heart Fail"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-023-00606-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-023-00606-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-023-00606-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T03:21:41Z","timestamp":1702610501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-023-00606-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1007\/s40292-023-00606-0","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,18]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involving human participants was reviewed and approved by the Research Ethics Commission of Ruijin Hospital (KY 2022\u2013154). The Research Ethics Committee approved the study protocol and waived the informed consent because of the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This work was supported by Clinical comprehensive evaluation and treatment management pathway of sav\/val in the real world of hypertension. Grant\/Award Number: SHYXHZP-2021-002.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All authors contributed to the study conception and design. Data collection and analysis were performed by YG, XL, JR, CZ, ZG. The first draft of the manuscript was written by YG and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}